 |
|
|
| |
Treatment With Sofosbuvir + Peginterferon + Ribavirin for 12 Weeks Achieves 90% SVR12 in Treatment-Naïve Genotype 1, 4, 5, and 6 HCV-Infected Patients: The NEUTRINO Study
|
| |
| |
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2
trial..........http://www.natap.org/2013/HCV/033113_02.htm
Eric Lawitz1, David Wyles2, Mitchell Davis3, Maribel Rodriguez-Torres4, K. Rajender Reddy5, Ira Jacobson6, Kris V. Kowdley7, Evguenia Svarovskaia8,
Deyuan Jiang8, John McNally8, Diana M. Brainard8, William T. Symonds8, John G. McHutchison8, Lisa Nyberg9, Zobair Younossi10
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 2University of California, San Diego, School of Medicine, La Jolla, CA, USA; 3DigestiveCARE-South Florida Center of Gastroenterology, Wellington, FL, USA; 4Fundacion de Investigacion, San Juan, Puerto Rico; 5University of
Pennsylvania, Philadelphia, PA, USA; 6Weill Cornell Medical College, New York, NY, USA; 7Digestive Diseases Institute, Virginia Mason Medical Center, Seattle, WA, USA; 8Gilead Sciences, Inc., Foster City, CA; USA; 9Kaiser Permanente, San Diego, CA, USA; 10Inova Fairfax Hospital, Falls Church, VA, USA
|
| |
|
|
|
|
|
